JP2023516568A - Sars-cov-2診断用組成物、キット及びこれを用いたsars-cov-2の診断方法 - Google Patents
Sars-cov-2診断用組成物、キット及びこれを用いたsars-cov-2の診断方法 Download PDFInfo
- Publication number
- JP2023516568A JP2023516568A JP2022549743A JP2022549743A JP2023516568A JP 2023516568 A JP2023516568 A JP 2023516568A JP 2022549743 A JP2022549743 A JP 2022549743A JP 2022549743 A JP2022549743 A JP 2022549743A JP 2023516568 A JP2023516568 A JP 2023516568A
- Authority
- JP
- Japan
- Prior art keywords
- coronavirus
- sars
- cov
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 241000711573 Coronaviridae Species 0.000 claims abstract description 36
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 35
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 28
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 28
- 238000003745 diagnosis Methods 0.000 claims abstract description 11
- 230000003321 amplification Effects 0.000 claims description 30
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 27
- 230000000295 complement effect Effects 0.000 claims description 12
- 238000011529 RT qPCR Methods 0.000 claims description 11
- 238000009396 hybridization Methods 0.000 claims description 11
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims description 11
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
- 108090000621 Ribonuclease P Proteins 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 22
- 102000004167 Ribonuclease P Human genes 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 101500023563 Severe acute respiratory syndrome coronavirus 2 Host translation inhibitor nsp1 Proteins 0.000 description 7
- 108091027544 Subgenomic mRNA Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000025721 COVID-19 Diseases 0.000 description 6
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108060004795 Methyltransferase Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside triphosphates Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
- 配列番号10の配列を含むコロナウイルス(SARS-CoV-2:Severe acute respiratory syndrome coronavirus 2)リーダ(leader)を特異的に増幅できる核酸オリゴマーを含む、コロナウイルス診断用組成物。
- 前記コロナウイルスリーダを特異的に増幅可能な核酸オリゴマーは、配列番号1又は配列番号2の配列を含むことを特徴とする、請求項1に記載の組成物。
- 前記核酸オリゴマーによって特異的に増幅されたコロナウイルスリーダ配列の産物に相補的に混成化できるプローブをさらに含む、請求項1に記載の組成物。
- 前記増幅されたコロナウイルスリーダに相補的に混成化できるプローブは、配列番号3の配列を含むことを特徴とする、請求項3に記載の組成物。
- 請求項1~4のいずれか一項に記載の組成物を含む、コロナウイルス診断用キット。
- 配列番号10の配列を含むコロナウイルス(SARS-CoV-2:Severe acute respiratory syndrome coronavirus 2)リーダ(leader)を特異的に増幅可能な核酸オリゴマーをサンプルに処理する段階を含む、コロナウイルス診断のための情報提供方法。
- 前記コロナウイルスリーダを特異的に増幅できる核酸オリゴマーは、配列番号1又は配列番号2の配列を含むことを特徴とする、請求項6に記載の方法。
- 前記核酸オリゴマーによって特異的に増幅されたコロナウイルスリーダ配列の産物に相補的に混成化できるプローブをさらに含む、請求項6に記載の方法。
- 前記増幅されたコロナウイルスリーダに相補的に混成化できるプローブは、配列番号3の配列を含むことを特徴とする、請求項8に記載の方法。
- 前記増幅は、RT-qPCR(Quantitative reverse transcription PCR)によって行われることを特徴とする、請求項6に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200028155 | 2020-03-06 | ||
KR10-2020-0028155 | 2020-03-06 | ||
PCT/KR2021/002735 WO2021177773A2 (ko) | 2020-03-06 | 2021-03-05 | Sars-cov-2 진단용 조성물, 키트 및 이를 이용한 sars-cov-2의 진단방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023516568A true JP2023516568A (ja) | 2023-04-20 |
JP7419552B2 JP7419552B2 (ja) | 2024-01-22 |
Family
ID=77612962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022549743A Active JP7419552B2 (ja) | 2020-03-06 | 2021-03-05 | Sars-cov-2診断用組成物、キット及びこれを用いたsars-cov-2の診断方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230057087A1 (ja) |
EP (1) | EP4116441A4 (ja) |
JP (1) | JP7419552B2 (ja) |
KR (1) | KR102555330B1 (ja) |
CN (1) | CN115803463A (ja) |
WO (1) | WO2021177773A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102665120B1 (ko) | 2021-01-13 | 2024-05-13 | 재단법인대구경북과학기술원 | ACE2에 결합하는 SARS-CoV2에 대한 항 바이러스 항체 및 이의 용도 |
CN113801966B (zh) * | 2021-11-03 | 2022-09-27 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种检测新型冠状病毒亚基因的荧光定量pcr方法及试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060017212A (ko) * | 2004-08-20 | 2006-02-23 | (주)지노믹트리 | 코로나바이러스 검출용 프로브 조성물, 프라이머 혼합물및 이를 이용한 코로나바이러스의 검출방법 |
JP2006523460A (ja) * | 2003-04-17 | 2006-10-19 | ジェン−プロウブ インコーポレイテッド | 試料中のsarsコロナウイルスの存在を決定するための組成物および方法 |
WO2016179509A1 (en) * | 2015-05-07 | 2016-11-10 | Emerging Viral Diagnostic Limited | Improved compositions and methods for detection of viruses |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897744B2 (en) * | 2003-04-28 | 2011-03-01 | The Public Health Agency Of Canada | SARS virus nucleotide and amino acid sequences and uses thereof |
KR100891399B1 (ko) * | 2007-02-14 | 2009-04-02 | 재단법인 목암생명공학연구소 | Sars 코로나바이러스진단용 프라이머, 프로브, 그 프라이머및/또는 프로브를 포함하는 키트 및 그 키트를 이용한진단방법 |
WO2021201996A1 (en) * | 2020-02-14 | 2021-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against respiratory viruses and methods of using the same |
JP2022544015A (ja) * | 2019-07-23 | 2022-10-17 | ユニバーシティ オブ ロチェスター | CRISPR-Casでの標的化されたRNA切断 |
EP4096712A4 (en) * | 2020-01-28 | 2024-05-08 | Codagenix Inc. | DE-OPTIMIZED SARS-COV-2 AND METHODS OF USE |
-
2021
- 2021-03-05 CN CN202180015768.4A patent/CN115803463A/zh active Pending
- 2021-03-05 WO PCT/KR2021/002735 patent/WO2021177773A2/ko unknown
- 2021-03-05 JP JP2022549743A patent/JP7419552B2/ja active Active
- 2021-03-05 US US17/759,067 patent/US20230057087A1/en active Pending
- 2021-03-05 EP EP21764053.1A patent/EP4116441A4/en active Pending
- 2021-03-05 KR KR1020210029217A patent/KR102555330B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006523460A (ja) * | 2003-04-17 | 2006-10-19 | ジェン−プロウブ インコーポレイテッド | 試料中のsarsコロナウイルスの存在を決定するための組成物および方法 |
KR20060017212A (ko) * | 2004-08-20 | 2006-02-23 | (주)지노믹트리 | 코로나바이러스 검출용 프로브 조성물, 프라이머 혼합물및 이를 이용한 코로나바이러스의 검출방법 |
WO2016179509A1 (en) * | 2015-05-07 | 2016-11-10 | Emerging Viral Diagnostic Limited | Improved compositions and methods for detection of viruses |
Non-Patent Citations (3)
Title |
---|
"Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome", GENBANK [ONLINE], JPN6023033323, 17 January 2020 (2020-01-17), ISSN: 0005129435 * |
JOURNAL OF CLINICAL MICROBIOLOGY, vol. 53, no. 8, JPN6023033325, 2015, pages 2722 - 2726, ISSN: 0005129433 * |
NATURE, vol. 579, JPN6023033324, 3 February 2020 (2020-02-03), pages 265 - 269, ISSN: 0005129434 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021177773A3 (ko) | 2021-10-28 |
EP4116441A4 (en) | 2024-04-03 |
KR102555330B1 (ko) | 2023-07-17 |
WO2021177773A2 (ko) | 2021-09-10 |
KR20210113083A (ko) | 2021-09-15 |
CN115803463A (zh) | 2023-03-14 |
JP7419552B2 (ja) | 2024-01-22 |
US20230057087A1 (en) | 2023-02-23 |
EP4116441A2 (en) | 2023-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100184015A1 (en) | Method for detection of xmrv | |
JP7419552B2 (ja) | Sars-cov-2診断用組成物、キット及びこれを用いたsars-cov-2の診断方法 | |
CN113981152A (zh) | 检测SARS-CoV-2变异株的组合物、试剂盒、方法及其用途 | |
JP6181742B2 (ja) | Hevアッセイ | |
JP5754100B2 (ja) | エンテロウイルス71rnaの検出方法および検出試薬 | |
WO2013111800A1 (ja) | Hiv検出用オリゴヌクレオチド、hiv検出キット、及びhiv検出方法 | |
JP2023523850A (ja) | 新型コロナウイルス(SARS-CoV-2)を検出するための手段および方法 | |
JP2005204664A (ja) | エンテロウィルス核酸の検出 | |
EP2568052A2 (en) | Primer composition for amplifying a gene region having various variations in a target gene | |
US20150031576A1 (en) | Real time pcr detection of m. tuberculosis resistant/susceptible to rifampicin and/or isoniazid | |
US20230416824A1 (en) | Systems for the detection of targeted gene variations and viral genomes and methods of producing and using same | |
JP6153515B2 (ja) | Hla−a*24:02を検出する方法、及び検出キット | |
JP2012143185A (ja) | 口蹄疫ウィルスの包括的検出方法 | |
JP2008306974A (ja) | Hcv遺伝子型判定方法、並びに、これに用いるlnaプローブ及びキット | |
US7026120B2 (en) | Probes for detecting tumor cells | |
CN115989323A (zh) | 检测SARS-CoV-2感染的方法 | |
US20100136513A1 (en) | Assay for sars coronavirus by amplification and detection of nucleocapsid rna sequence | |
JP4534627B2 (ja) | サイトメガロウイルスの検出および定量方法 | |
US10858711B2 (en) | Primers, probes and methods for sensitive, specific detection and monitoring of HIV-1 and HCV | |
US8258283B2 (en) | Method for detection of HCV at the real time PCR with intercalating dye | |
EP4146821A1 (en) | Methods and compositions for detecting sars-cov-2 nucleic acid | |
JP2023036344A (ja) | SARS-CoV-2の型を判定する方法、前記方法に用いるプローブセット及び前記方法に用いるプライマープローブセット | |
JP2007306817A (ja) | Rsウイルスを検出するためのポリヌクレオチド及びこれを用いた検出方法 | |
JP2018068140A (ja) | Abl遺伝子増幅用プライマー、核酸増幅方法及び核酸増幅用キット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220908 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230815 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231109 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240110 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7419552 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |